CClinicalTrials.gg
Sign In
CompletedNCT05958420Updated Jul 24, 2023

Evaluation of HDL Subfraction Changes and HDL-Associated Enzymes in Liver Failure Patients and Healthy Donors

An observational study in Liver Failure, sponsored by Akdeniz University. Completed at 1 site in Turkey. Per ClinicalTrials.gov, last updated 2023-07-24.

Sponsored by Akdeniz University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
40
Sex
All
01

Study summary

This study aimed to determine high-density lipoprotein (HDL) subfraction profile and HDL-associated enzyme changes in liver failure patients and healthy donors.

Read the detailed description

Objectives: This study aimed to determine high-density lipoprotein (HDL) subfraction profile and HDL-associated enzyme changes in liver failure patients and healthy donors.

Materials and Methods: Twenty liver failure patients and twenty healthy donors are selected. Blood samples obtained from all patients prior to transplant will analyzed. HDL subfraction analysis will done by continuous disc polyacrylamide gel electrophoresis. Plasma levels of apolipoprotein A-1 (ApoA-I), cholesteryl ester transfer protein (CETP), and lecithin-cholesterol acyltransferase (LCAT) will determined by enzyme-linked immunosorbent assay.

02

Conditions studied

  • Liver Failure

Keywords

  • Liver Failure
  • HDL Subfractions
  • ApoA1
  • CETP
  • LCAT
03

In context

Liver Failure

445 studies on the registry are indexed under Liver Failure; 69 are open to participants now.

This study's enrollment of 40 is below the median of 129 across 146 observational studies indexed under Liver Failure.

Browse Liver Failure studies →

Lead sponsor

Akdeniz University is the lead sponsor of 289 studies on the registry; 60 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All consecutive patients who underwent living donor LT procedure between 2018 and 2019.

Inclusion criteria

  • Liver failure patients

Exclusion criteria

Exclusion Criteria:

  • patients not giving consent
  • Participants who had oncological and hematological diseases, coronary failure, kidney failure, malnutrition, diabetes, traumatic brain injury, or cadaveric LT and who were using psychoactive medicines or having a respiratory system or CNS diseases were excluded from the study
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
40 participants (actual)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • Group 1

    Patients with liver failure

  • Group 2

    Healthy donors

06

What researchers measure

Primary outcomes

  1. HDL Subfractions

    Evaluation of HDL Subfractions in groups

    Time frame: Blood will collected from all patients before surgery

Secondary outcomes

  1. HDL-associated enzymes

    ApoA1, CETP and LCAT levels in groups

    Time frame: Blood will collected from all patients before surgery

07

Study locations

1 site
  • AkdenizU
    Antalya, Turkey
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05958420
Lead sponsor
Akdeniz University
Responsible party
İlker Onguc Aycan (Prof. Dr. İlker Öngüç Aycan, Akdeniz University) — Principal investigator
First posted
Jul 24, 2023
Start date
Jan 1, 2020
Primary completion
Jan 15, 2022
Completion
Jan 15, 2022
Last update
Jul 24, 2023

Study contacts

İlker O Aycan
study chair · Akdeniz University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Liver Failure→

Other studies from this sponsor

Akdeniz University

Start the discussion